Performance Measurement Network

Question: Is Xarelto (Rivaroxaban) an acceptable anticoagulant for STK-3?

If a patient is discharged on Xarelto would that abstract as 'Yes' for discharged on anticoagulant therapy?


Dear Primary Vendor Contact: The Joint Commission is aware that the FDA has recently approved the use of the Oral Factor Xa called rivaroxaban (Xarelto) in atrial fibrillation patients in addition to hip and knee replacement patients for VTE prophylaxis. However, this decision coincided with the deadline for revision of the CMS/Joint Commission aligned Specifications Manual for National Hospital Inpatient Quality Measures version 4.1, and therefore measure revisions accommodating the use of Oral Factor Xa in these patients for the VTE and STK performance measure sets could not be made. Such revisions will be included in future versions of the manual. In the meantime, rest assured that hospitals will not be penalized for the use of Oral Factor Xa for STK or VTE patients who also have atrial fibrillation. Until appropriate measure specifications revisions can be made, STK or VTE patients who receive Oral Factor Xa will not be counted in the measure populations for the STK or VTE measure sets. Further questions can be directed to: Thank you for your patience in this revision process.

Question Details
Focus area(s): Chart Abstracted Measure Specifications – Clinical
Related documents: STK-03, Patient Discharged on Anticoagulation Therapy, ,

Copyright © by the contributing authors. All material on this collaboration platform is the property of the contributing authors.
Ideas, requests, problems regarding Performance Measurement Network? Send feedback
This website is using cookies. More info. That's Fine